Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
Atsuo TakashimaTetsuya HamaguchiJunki MizusawaFumio NagashimaMasahiko AndoHitoshi OjimaTadamichi DendaJun WatanabeKatsunori ShinozakiHideo BabaMasako AsayamaSeiji HasegawaToshiki MasuishiKen NakataShunsuke TsukamotoHiroshi KatayamaKenichi NakamuraHaruhiko FukudaYukihide KanemitsuYasuhiro Shimadanull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.
Keyphrases
- phase iii
- metastatic colorectal cancer
- open label
- double blind
- phase ii
- clinical trial
- placebo controlled
- phase ii study
- study protocol
- community dwelling
- locally advanced
- physical activity
- middle aged
- liver metastases
- cross sectional
- squamous cell carcinoma
- radiation therapy
- randomized controlled trial
- low density lipoprotein
- rectal cancer